Evolving Options for HBV Therapy: Navigating the New Treatment Landscape

Learn patient-specific HBV treatment recommendations from our panel of experts using this Interactive Decision Support Tool, Virtual Presentation, and expert-authored commentaries.
Robert S. Brown, Jr., MD, MPH
Natalie H. Bzowej, MD, PhD
Jordan J. Feld, MD, MPH
Norah Terrault, MD, MPH
Tram T. Tran, MD


Would you treat or monitor a patient with low HBV DNA levels and high ALT? Here’s my take.

Tram T. Tran, MD Released: February 21, 2018

Who are the rare patients with hepatitis B infection who can benefit from peginterferon? Here’s my take.

Robert S. Brown, Jr., MD, MPH Released: May 21, 2018

When should we recommend waiting vs starting treatment in women planning to conceive and those who are already in the early or late stages of pregnancy?

Natalie H. Bzowej, MD, PhD Released: June 8, 2018

Norah Terrault, MD, MPH, has disclosed that she has received consulting fees from Dynavax Technologies, Gilead Sciences, and Novartis and funds for research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck.

Norah Terrault, MD, MPH Released: July 23, 2018

How do renal dysfunction, insurance coverage, and long-term safety concerns affect whether we should recommend TAF, TDF, or entecavir to our patients starting HBV therapy?

Jordan J. Feld, MD, MPH Released: August 17, 2018

Patients with low levels of HBV DNA are at greater risk of HCC, particularly those with cirrhosis. Read how I evaluate for causes of low-level viremia and manage patients in this situation.

Robert S. Brown, Jr., MD, MPH Released: September 24, 2018
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)

Educational grant provided by:
Gilead Sciences

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?